Neoadjuvant Immunotherapy of Operable Metastatic Melanoma in Real Life (GCC)

Primary outcomes

• Complete histological response [Day 1]: Histological response rate on histological analysis of the resected specimen

Secondary outcomes

• Objectival response rate [Day 1]: Objectival response rate on imaging
• Event-free survival [Month 12]: An event is defined by progression of the disease or toxicity making surgery impossible, the impossibility of starting adjuvant treatment within 84 days following surgery, recurrence of melanoma after surgery or death.
• Disease Free Survival after surgery [Month 12]
• Overall survival [Month 18]
• Metastases-free survival [Month 18]
• Frequency of toxicities [Month 12]: According to Common Terminology Criteria for Adverse Events (CTCAE) v5, grades III and IV
• Severity of toxicities [Month 12]: According to CTCAE v5, grades III and IV

Sex: All, ages: 18 Years to any

Inclusion Criteria:

* Patients with operable metastatic melanoma (stage III or IV of American Joint Committee on Cancer \[AJCC\] Stages CLassification) treated with neoadjuvant immunotherapy (anti-PD1 or anti-PD1 + anti-CTLA-4), even if surgery cancelled due to disease progression or complete response or patient\'s refusal to be operated.
* Efficacy of the neoadjuvant immunotherapy histologically of radiologically assessed

Exclusion Criteria:

* Uveal melanoma